News
In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...
Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback